EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group

Antonio Sahuquillo-Torralba, Miguel Mansilla-Polo iD, Conrad Pujol-Marco, Mar Llamas-Velasco, Eva V Rull, Ricardo Ruiz Villaverde iD, Marta Ferran, Gerard Pitarch, Anna Lopez, Emma Beltran, Ana Urruticoechea-Arana, Josep Riera-Monroig und 9 weitere

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17238 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Antonio Sahuquillo-Torralba und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria (IIS) La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Certolizumab Pegol, Psoriasis, Severity of Illness Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Certolizumab is an Fc‐free PEGylated tumor necrosis factor‐alpha (TNFα) inhibitor recently approved for the treatment of moderate‐to‐severe plaque psoriasis, although there is limited real‐world evidence on the effectiveness and safety in patients with plaque psoriasis treated with certolizumab. The objective of this article is to determine the effectiveness, drug survival, and safety, including pregnancy, childbirth, and lactation, of certolizumab in moderate‐to‐severe plaque psoriasis under real‐world conditions.

Methods

This is a retrospective, multicenter, observational study performed in 15 hospitals in Spain. It evaluates the effectiveness and safety of certolizumab in plaque psoriasis in the clinical practice setting.

Results

A total of 67 patients (73% female) were evaluated with a mean baseline Psoriasis Area Severity Index (PASI) of 8.9. At Week 12, the mean PASI was 2.3 ( n = 67), 1.3 ( n = 57) at Week 24 and 1.3 at Week 52 ( n = 34). Absolute PASI < 3 was achieved in 69, 86, and 92% of patients at Weeks 12, 24, and 52, respectively, as observed. For its part, using the under‐response imputation analysis, PASI < 3 at Weeks 12, 24, and 52 were achieved by 69, 73, and 49% of the patients, respectively. A total of 35 patients (52%) had concomitant psoriatic arthritis, and, in 24 of them, Disease Activity in Psoriatic Arthritis Score (DAPSA) was recorded at baseline, with a mean value of 17.9 which decreased to 8.2 at Week 12 ( n = 22) and to 3.6 at Week 24 ( n = 18). Certolizumab treatment was discontinued in 14 out of 67 patients (21%), due to lack/loss of cutaneous or articular effectiveness ( n = 11) or patient decision ( n = 2) or adverse event in only one patient who developed active tuberculosis. A lower baseline PASI [hazard ratio (HR): 1.12 (1.02–1.23); P = 0.023] and a more significant reduction in PASI at Week 12 [HR: 1.16 (1.07–1.27); P < 0.001] and Week 52 [HR: 1.47 (1.11–1.96); P = 0.007] was shown to be significantly related with better survival for the entire follow‐up period. Fourteen patients were treated during pregnancy and/or lactation without reporting adverse events in either the patient or the newborn.

Conclusions

Certolizumab consistently showed high effectiveness and drug survival rates in this real‐life cohort. The safety demonstrated in clinical trials during pregnancy and lactation seems to be confirmed in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Certolizumab PegolPsoriasisSeverity of Illness IndexHumansRetrospective StudiesFemaleMaleAdultSpainPregnancyMiddle AgedTreatment OutcomeBreast FeedingAgedPregnancy Complications

Stichwörter der Autor:innen

certolizumabevidencepregnancypsoriasisreal world

Substanzen

Certolizumab Pegol

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria (IIS) La Fe, Valencia, Spain.
  • Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.
  • Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
  • Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions, Barcelona, Spain.
  • Department of Dermatology, Hospital General Universitario, Castellón, Spain.

ORCID-Profile: Miguel Mansilla-Polo, Ricardo Ruiz Villaverde, Isabel Belinchón Romero, José M Carrascosa, Víctor Gonzalez-Delgado

Zitieren

APA

Sahuquillo-Torralba, A., Mansilla-Polo, M., Pujol-Marco, C., Llamas-Velasco, M., Rull, E. V., Ruiz Villaverde, R., Ferran, M., Pitarch, G., Lopez, A., Beltran, E., Urruticoechea-Arana, A., Riera-Monroig, J., Alsina, M., Vidal, D., Belinchón Romero, I., Notario, J., Carrascosa, J. M., Gonzalez-Delgado, V., Mollet, J., …, & Gallardo, F. (2024). Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group. International Journal of Dermatology. https://doi.org/10.1111/ijd.17238

Vancouver

Sahuquillo-Torralba A, Mansilla-Polo M, Pujol-Marco C, Llamas-Velasco M, Rull EV, Ruiz Villaverde R, et al. Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group. International Journal of Dermatology. 2024. doi:10.1111/ijd.17238

BibTeX
@article{SahuquilloTorralba2024,
  author = {Sahuquillo-Torralba, Antonio and Mansilla-Polo, Miguel and Pujol-Marco, Conrad and Llamas-Velasco, Mar and Rull, Eva V and Ruiz Villaverde, Ricardo and Ferran, Marta and Pitarch, Gerard and Lopez, Anna and Beltran, Emma and Urruticoechea-Arana, Ana and Riera-Monroig, Josep and Alsina, Merce and Vidal, David and Belinchón Romero, Isabel and Notario, Jaime and Carrascosa, José M and Gonzalez-Delgado, Víctor and Mollet, Jordi and Ribera, Miquel and Gallardo, Fernando},
  title = {Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17238}
}
Kostenlos starten →